<DOC>
	<DOCNO>NCT01107639</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-ray kill tumor cell . Drugs use chemotherapy , docetaxel cisplatin , work different way stop growth tumor cell , either kill cell stop dividing . Monoclonal antibody , cetuximab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . It yet know whether give radiation therapy together chemotherapy effective without cetuximab treat patient esophageal cancer . PURPOSE : This randomized phase III trial study give radiation therapy together chemotherapy , without cetuximab , follow surgery treating patient locally advanced esophageal cancer remove surgery .</brief_summary>
	<brief_title>Radiation Therapy Chemotherapy , With Without Cetuximab , Followed Surgery Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine efficacy neoadjuvant radiochemotherapy comprise docetaxel , cisplatin , radiotherapy combination cetuximab follow surgery adjuvant cetuximab versus neoadjuvant radiochemotherapy comprise docetaxel , cisplatin , radiotherapy follow surgery patient locally advanced esophageal carcinoma . Secondary - To compare toxicity two therapy arm . - To determine pattern failure overall regard histology . - To evaluate economic aspect subproject perform radiotherapy quality assurance program . OUTLINE : This multicenter study . Patients stratify accord center , histology ( adenocarcinoma vs squamous cell carcinoma ) , primary tumor ( T2 vs T3-4 ) , gender ( male v female ) . Patients randomize 1 2 treatment arm . - Arm A : - Induction chemotherapy ( docetaxel cisplatin ) concurrent cetuximab Patients receive docetaxel IV 1 hour cisplatin IV 1 hour day 1 cetuximab IV 1-2 hour day 1 , 8 , 15 . Treatment repeat every 21 day 2 course . - Chemotherapy ( docetaxel cisplatin ) , cetuximab , concurrent radiotherapy Beginning week 7 , patient receive cetuximab IV 1 hour , docetaxel IV 30 minute , cisplatin IV 1 hour day 43 , 50 , 57 , 64 , 71 undergo radiotherapy 5 day week 5 week . Patients undergo surgery 4-7 week completion radiotherapy . - Adjuvant cetuximab Beginning 3-6 week completion surgery , patient receive cetuximab IV 1-2 hour every 2 week total 6 dos . - Arm B : Patients receive induction chemotherapy comprise docetaxel IV cisplatin IV 2 course arm A . Beginning week 7 , patient receive docetaxel IV , cisplatin IV , concurrent radiotherapy 5 week arm A . Patients undergo surgery 4-7 week completion radiotherapy . After completion study therapy , patient follow 1 ( arm B ) 6 ( arm A ) month , every 3 month 3 year , every 6 month 2 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm esophageal carcinoma Meets follow criterion : Resectable , locally advanced disease determine combination CT scan , endoluminal ultrasound ( EUS ) , PET scan , multidisciplinary team discussion T2 , N13 ; T3 , N ; T4a , N ( technically resectable curative intent [ R0 ] decide multidisciplinary team discussion ) EUSguided fineneedle aspiration ( FNA ) allow , determines nodal status positive FNA No T1 , N , M0 ; T2 , N0 , M0 ; T4a ( due infiltration tracheabronchial tree organ involvement operate curative intent [ R0 ] decide multidisciplinary team discussion ) ; T4b ; distant metastasis ( M1 ) Type I II disease accord Siewert classification Squamous cell carcinoma ( include basaloidsquamous cell adenosquamous carcinoma ) adenocarcinoma thoracic esophagus esophagogastric junction ( 5 cm entrance esophagus thorax gastric cardia ) Patients obstructive tumor eligible ( obstructive tumor consider locally advanced tumor ) No cervical esophageal carcinoma tumor involve first 5 cm thoracic esophagus No airway infiltration case tumor tracheal bifurcation No peritoneal carcinomatosis case adenocarcinoma infiltrate gastric cardia ( i.e. , esophagogastric junction carcinoma Siewert type I II ) PATIENT CHARACTERISTICS : WHO performance status 01 Neutrophil count ≥ 1.5 x 10^9/L Platelet count ≥ 100 x 10^9/L Creatinine clearance &gt; 60 mL/min Bilirubin ≤ 1.0 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN AST ≤ 1.5 time ULN INR normal PTT ≤ 1.0 time ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 12 month completion study therapy FEV_1 ≥ 1.5 L OR ≥ 75 % reference value Must compliant geographically proximal stag followup Considered operable ( i.e. , appropriate organ function ability undergo general anesthesia ) No malignancy within past 5 year except nonmelanomatous skin cancer adequately treat carcinoma situ cervix No severe uncontrolled cardiovascular disease , include follow : NYHA class IIIIV congestive heart failure Unstable angina pectoris Myocardial infarction within past 12 month Significant arrhythmias No psychiatric disorder preclude understanding information trial related topic , give informed consent , answer questionnaire No active uncontrolled infection No serious underlie medical condition , opinion investigator , could impair ability patient participate trial ( e.g. , uncontrolled diabetes mellitus active autoimmune disease ) No preexist peripheral neuropathy &gt; grade 1 No definite contraindication use corticosteroid antihistamine premedication No known hypersensitivity trial drug hypersensitivity component trial drug PRIOR CONCURRENT THERAPY : No prior chemotherapy radiotherapy chest At least 30 day since prior treatment another clinical trial No concurrent drug contraindicate use trial drug No concurrent anticancer treatments No concurrent experimental drug investigational treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage IIB esophageal cancer</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma gastroesophageal junction</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>stage IIIA esophageal cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
</DOC>